Skip to main content

Next generation eco-friendly, microbiome preserving and reduced resistance therapeutics

Project description

Highly selective antibiotics may fight highly resistant human pathogens

Antibiotics (literally 'against life') kill bacteria. As our bodies are host to many 'good' bacteria, selective antibiotics are needed. Ribosomes are the site of protein synthesis and the target of novel therapeutics under development by NEXTER. The key is in targeting certain portions of ribosomes that are specific to certain species of bacteria. Using this strategy, scientists have stopped the growth of a multi-drug resistant strain of Staphylococcus aureus (S. aureus), an important human pathogen causing infection in both clinical and community settings. Further, these synthetic therapeutics are degradable meaning they will decrease environmental contamination, further reducing the development of resistant strains. The team is now targeting other pathogens and plans to take the pioneering technology to market soon.

Call for proposal

ERC-2019-PoC
See other projects for this call

Funding Scheme

ERC-POC-LS - ERC Proof of Concept Lump Sum Pilot

Host institution

WEIZMANN INSTITUTE OF SCIENCE
Address
Herzl Street 234
7610001 Rehovot
Israel
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 150 000

Beneficiaries (1)

WEIZMANN INSTITUTE OF SCIENCE
Israel
EU contribution
€ 150 000
Address
Herzl Street 234
7610001 Rehovot
Activity type
Higher or Secondary Education Establishments